Role of oxidative stress and molecular changes in liver fibrosis: A review

Current Medicinal Chemistry

Volumn 19, Issue 28, 2012, Pages 4850-4860

  Sanchez Valle V ^a   Chavez Tapia N C ^a   Uribe, M ^a   Mendez Sanchez N ^a  

^a LIVER RESEARCH UNIT   (Mexico)

Author keywords

Antioxidants; Cirrhosis; Cytokine; Fibrosis; Hepatic stellate cells; Inflammation; Liver; Nitric oxide; Oxidative stress; Reactive oxygen species

Indexed keywords

CATALASE; CURCUMIN; CYCLOSPORIN A; FARGLITAZAR; GENISTEIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; IRBESARTAN; MALOTILATE; OBETICHOLIC ACID; PEGINTERFERON ALPHA2A; PENTOXIFYLLINE; PIRFENIDONE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SILYMARIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA; WARFARIN; XANTHINE OXIDASE;

APOPTOSIS; ARTICLE; CATALYSIS; CELL ADHESION; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; DISEASE COURSE; FENTON REACTION; FIBROGENESIS; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; KUPFFER CELL; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER PROTECTION; MOLECULARLY TARGETED THERAPY; NITROSATIVE STRESS; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; STELLATE CELL;

ANTIOXIDANTS; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING;

EID: 84870461648     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803341520     Document Type: Article

References (121)

1. Li, J.; Fan, R.; Zhao, S.; Liu, L.; Guo, S.; Wu, N.; Zhang, W.; Chen, P. Reactive oxygen species released from hypoxic hepatocytes regulates MMP- 2 expression in hepatic stellate cells. Int. J. Mol. Sci., 2011, 12, 2434-2447.
2. Fabre, V.; Wu, H.; PondTor, S.; Coutinho, H.; Acosta, L.; Jiz, M.; Olveda, R.; Cheng, L.; White, E.S.; Jarilla, B.; McGarvey, S.T.; Friedman, J.F.; Kurtis, J.D., J Infect Dis.,2011, 203, (5), 707-714.
3. Anthony, P.P.; Ishak, K.G.; Nayak, N.G.; Poulsen, H.E.; Scheuer, P.J.; Sobin, L.H. The morphology of cirrhosis: recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J. Clin. Pathol., 1978, 31, 395-414.
4. Baranova, A.; Lal, P.; Birerdinc, A.; Younossi, Z. M., Non-invasive markers for hepatic fibrosis. BMC Gastroenterol.,2011, 17,11-91.
5. Parola, M.; Robino, G., Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001, 35 (2), 297-306.
6. Sies, H.; Cadenas, E. Oxidative stress: damage to intact cells and organs. Philos. Trans. R. Soc. Lond. B Biol. Sci., 1985, 311(1152), 617-663.
7. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine, 3rd ed.; Oxford University Press: USA 1999.
8. Kang, K. J., Mechanism of hepatic ischemia/reperfusion injury and protection against reperfusion injury. Transplant Proc., 2002, 34 (7), 2659-61.
9. Jaeschke, H., Reactive oxygen and mechanisms of inflammatory liver injury. J Gastroenterol Hepatol., 2000, 15 (7), 718-24.
10. Ha, H. L.; Shin, H. J.; Feitelson, M. A.; Yu, D. Y., Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol., 2010, 16 (48), 6035-43.
11. Miller, D. M.; Buettner, G. R.; Aust, S. D., Transition metals as catalysts of "autoxidation" reactions. Free Radic Biol Med., 1990, 8 (1), 95-108.
12. Valko, M.; Morris, H.; Cronin, M. T., Metals, toxicity and oxidative stress. Curr Med Chem., 2005, 12 (10), 1161-208.
13. Kovacic, P.; Pozos, R. S.; Somanathan, R.; Shangari, N.; O'Brien, P. J., Mechanism of mitochondrial uncouplers, inhibitors, and toxins: focus on electron transfer, free radicals, and structure-activity relationships. Curr Med Chem., 2005, 12 (22), 2601-23.
14. Pastor, N.; Weinstein, H.; Jamison, E.; Brenowitz, M., A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence-specific binding. J Mol Biol., 2000, 304 (1), 55-68.
15. Leonard, S. S.; Harris, G. K.; Shi, X., Metal-induced oxidative stress and signal transduction. Free Radic Biol Med., 2004, 37 (12), 1921-42.
16. Liochev, S. I.; Fridovich, I., The Haber-Weiss cycle - 70 years later: an alternative view. Redox Rep., 2002, 7 (1), 55-7; author reply 59-60.
17. Kakhlon, O.; Cabantchik, Z. I., The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med., 2002, 33 (8), 1037-46.
18. De Grey, A. D., HO2: the forgotten radical. DNA Cell Biol., 2002, 21 (4), 251-7.
19. Aikens, J.; Dix, T. A., Perhydroxyl radical (HOO.) initiated lipid peroxidation. The role of fatty acid hydroperoxides. J Biol Chem., 1991, 266 (23), 15091-8.
20. Vorbach, C.; Harrison, R.; Capecchi, M. R., Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol., 2003, 24 (9), 512-7.
21. Valko, M.; Izakovic, M.; Mazur, M.; Rhodes, C. J.; Telser, J., Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem., 2004, 266 (1-2), 37-56.
22. Decoursey, T. E.; Ligeti, E., Regulation and termination of NADPH oxidase activity. Cell Mol Life Sci., 2005, 62 (19-20), 2173-93.
23. Ghafourifar, P.; Cadenas, E., Mitochondrial nitric oxide synthase. Trends Pharmacol Sci., 2005, 26 (4), 190-5.
24. Bergendi, L.; Benes, L.; Durackova, Z.; Ferencik, M., Chemistry, physiology and pathology of free radicals. Life Sci., 1999, 65 (18-19), 1865-74.
25. Chiueh, C. C., Neuroprotective properties of nitric oxide. Ann N Y Acad Sci., 1999, 890, 301-11.
26. Ridnour, L. A.; Thomas, D. D.; Mancardi, D.; Espey, M. G.; Miranda, K. M.; Paolocci, N.; Feelisch, M.; Fukuto, J.; Wink, D. A., The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem., 2004, 385 (1), 1-10.
27. Carr, A. C.; McCall, M. R.; Frei, B., Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol., 2000, 20 (7), 1716-23.
28. Okuda, M.; Li, K.; Beard, M. R.; Showalter, L. A.; Scholle, F.; Lemon, S. M.; Weinman, S. A., Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology., 2002, 122 (2), 366-75.
29. Reid, A. E., Nonalcoholic steatohepatitis. Gastroenterology., 2001, 121 (3), 710-23.
30. Guimaraes, E. L.; Franceschi, M. F.; Grivicich, I.; Dal-Pizzol, F.; Moreira, J. C.; Guaragna, R. M.; Borojevic, R.; Margis, R.; Guma, F. C., Relationship between oxidative stress levels and activation state on a hepatic stellate cell line. Liver Int., 2006, 26 (4), 477-85.
31. Muriel, P., Role of free radicals in liver diseases. Hepatol Int.,2009,3,526-26.
32. Koek, G.H.; Liedorp, P.R.; Bast, A., The role of oxidative stress in nonalcoholic steatohepatitis. Clin Chim Acta., 2011, (412), 1297-1305.
33. Mates, J. M., Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology., 2000, 153 (1-3), 83-104.
34. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M. T.; Mazur, M.; Telser, J., Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol., 2007, 39 (1), 44-84.
35. Inoue M. Protective mechanisms against reactive oxygen species. In: Arias IM, Fausto N, Jakoby WB, Schachter D, Shafritz DA, editors. The Liver: Biology and Pathobiology, New York: Raven, 1994. pp.443-459.
36. Goldstein, S.; Czapski, G., The reaction of NO. with O2.- and HO2.: a pulse radiolysis study. Free Radic Biol Med., 1995, 19 (4), 505-10.
37. Pryor, W. A.; Squadrito, G. L., The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol., 1995, 268 (5 Pt 1), L699-722.
38. MacMillan-Crow, L. A.; Crow, J. P.; Kerby, J. D.; Beckman, J. S.; Thompson, J. A., Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A., 1996, 93 (21), 11853-8.
39. Bonfoco, E.; Krainc, D.; Ankarcrona, M.; Nicotera, P.; Lipton, S. A., Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A., 1995, 92 (16), 7162-6.
40. Fernandez-Checa, J. C.; Kaplowitz, N., Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol., 2005, 204 (3), 263-73.
41. Ha, H.L.; Shin, H.J.; Feitelson, M.A.; Yu, D.Y., Oxidative stress and antioxidants in hepatic pathogenesis. World J Gastroenterol., 2010,16 (48), 6035-6043.
42. Pinzani, M.; Rombouts, K., Liver fibrosis: from the bench to clinical targets. Dig Liver Dis., 2004, 36 (4), 231-42.
43. Bataller, R.; Brenner, D. A., Liver fibrosis. J Clin Invest., 2005, 115 (2), 209-18.
44. Hernandez-Gea, V.; Friedman, S. L., Pathogenesis of liver fibrosis. Annu Rev Pathol.,2011,6, 425-56.
45. Pinzani, M.; Rombouts, K.; Colagrande, S., Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol., 2005, 42 Suppl (1), S22-36.
46. Chakraborty, J.B.; Oakley, F.; Walsh, M.J., Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol, 2012, 648915.
47. Kmiec, Z., Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol, 2001, 161, III-XIII, 1-151.
48. Friedman, S. L., Mechanisms of hepatic fibrogenesis. Gastroenterology., 2008, 134 (6), 1655-69.
49. Bilzer, M.; Roggel, F.; Gerbes, A. L., Role of Kupffer cells in host defense and liver disease. Liver Int., 2006, 26 (10), 1175-86.
50. Canbay, A.; Higuchi, H.; Bronk, S. F.; Taniai, M.; Sebo, T. J.; Gores, G. J., Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology., 2002, 123 (4), 1323-30.
51. Canbay, A.; Feldstein, A. E.; Higuchi, H.; Werneburg, N.; Grambihler, A.; Bronk, S. F.; Gores, G. J., Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology., 2003, 38 (5), 1188-98.
52. Borkham-Kamphorst, E.; van Roeyen, C. R.; Ostendorf, T.; Floege, J.; Gressner, A. M.; Weiskirchen, R., Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol., 2007, 46 (6), 1064-74.
53. Wong, L.; Yamasaki, G.; Johnson, R. J.; Friedman, S. L., Induction of betaplatelet- derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest., 1994, 94 (4), 1563-9.
54. Lechuga, C. G.; Hernandez-Nazara, Z. H.; Hernandez, E.; Bustamante, M.; Desierto, G.; Cotty, A.; Dharker, N.; Choe, M.; Rojkind, M., PI3K is involved in PDGF-beta receptor upregulation post-PDGF-BB treatment in mouse HSC. Am J Physiol Gastrointest Liver Physiol., 2006, 291 (6), G1051-61.
55. Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Noguchi, R.; Hicklin, D. J.; Wu, Y.; Yanase, K.; Namisaki, T.; Yamazaki, M.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H., Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut., 2003, 52 (9), 1347-54.
56. Steiling, H.; Muhlbauer, M.; Bataille, F.; Scholmerich, J.; Werner, S.; Hellerbrand, C., Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am J Pathol., 2004, 165 (4), 1233-41.
57. Kinnman, N.; Hultcrantz, R.; Barbu, V.; Rey, C.; Wendum, D.; Poupon, R.; Housset, C., PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest., 2000, 80 (5), 697-707.
58. Bonacchi, A.; Romagnani, P.; Romanelli, R. G.; Efsen, E.; Annunziato, F.; Lasagni, L.; Francalanci, M.; Serio, M.; Laffi, G.; Pinzani, M.; Gentilini, P.; Marra, F., Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem., 2001, 276 (13), 9945-54.
59. Melton, A. C.; Yee, H. F., Hepatic stellate cell protrusions couple plateletderivedgrowth factor-BB to chemotaxis. Hepatology., 2007, 45 (6), 1446-53.
60. Inagaki, Y.; Okazaki, I., Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut., 2007, 56 (2), 284-92.
61. George, J.; Wang, S. S.; Sevcsik, A. M.; Sanicola, M.; Cate, R. L.; Koteliansky, V. E.; Bissell, D. M., Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am J Pathol., 2000, 156 (1), 115-24.
62. Gao, R.; Brigstock, D. R., Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem., 2004, 279 (10), 8848-55.
63. Paradis, V.; Perlemuter, G.; Bonvoust, F.; Dargere, D.; Parfait, B.; Vidaud, M.; Conti, M.; Huet, S.; Ba, N.; Buffet, C.; Bedossa, P., High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology., 2001, 34 (4 Pt 1), 738-44.
64. Brigstock, D. R., The CCN family: a new stimulus package. J Endocrinol.,2003, 178 (2), 169-75.
65. Arthur, M. J., Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol., 2000, 279 (2), G245-9.
66. O'Byrne, S. M.; Wongsiriroj, N.; Libien, J.; Vogel, S.; Goldberg, I. J.; Baehr, W.; Palczewski, K.; Blaner, W. S., Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT). J Biol Chem., 2005, 280 (42), 35647-57.
67. Friedman, S. L.; Bansal, M. B., Reversal of hepatic fibrosis - fact or fantasy? Hepatology., 2006, 43 (2 Suppl 1), S82-8.
68. Radaeva, S.; Sun, R.; Jaruga, B.; Nguyen, V. T.; Tian, Z.; Gao, B., Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology., 2006, 130 (2), 435-52.
69. Oakley, F.; Trim, N.; Constandinou, C. M.; Ye, W.; Gray, A. M.; Frantz, G.; Hillan, K.; Kendall, T.; Benyon, R. C.; Mann, D. A.; Iredale, J. P., Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. Am J Pathol., 2003, 163 (5), 1849-58.
70. Ruddell, R. G.; Oakley, F.; Hussain, Z.; Yeung, I.; Bryan-Lluka, L. J.; Ramm, G. A.; Mann, D. A., A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol., 2006, 169 (3), 861-76.
71. Krizhanovsky, V.; Yon, M.; Dickins, R. A.; Hearn, S.; Simon, J.; Miething, C.; Yee, H.; Zender, L.; Lowe, S. W., Senescence of activated stellate cells limits liver fibrosis. Cell., 2008, 134 (4), 657-67.
72. Green, M. R., Senescence: not just for tumor suppression. Cell., 2008, 134 (4), 562-4.
73. Galli, A.; Svegliati-Baroni, G.; Ceni, E.; Milani, S.; Ridolfi, F.; Salzano, R.; Tarocchi, M.; Grappone, C.; Pellegrini, G.; Benedetti, A.; Surrenti, C.; Casini, A., Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology., 2005, 41 (5), 1074-84.
74. Wei, C. L.; Lee, K. H.; Khoo, H. E.; Hon, W. M., Expression of haem oxygenase in cirrhotic rat liver. J Pathol., 2003, 199 (3), 324-34.
75. Guimaraes, E. L.; Franceschi, M. F.; Grivicich, I.; Dal-Pizzol, F.; Moreira, J. C.; Guaragna, R. M.; Borojevic, R.; Margis, R.; Guma, F. C., Relationship between oxidative stress levels and activation state on a hepatic stellate cell line. Liver Int., 2006, 26 (4), 477-85.
76. Sarsour, E. H.; Kumar, M. G.; Chaudhuri, L.; Kalen, A. L.; Goswami, P. C., Redox control of the cell cycle in health and disease. Antioxid Redox Signal., 2009, 11 (12), 2985-3011.
77. Nilsen, T. W., Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet., 2007, 23 (5), 243-9.
78. Yekta, S.; Tabin, C. J.; Bartel, D. P., MicroRNAs in the Hox network: an apparent link to posterior prevalence. Nat Rev Genet., 2008, 9 (10), 789-96.
79. Pillai, R. S.; Bhattacharyya, S. N.; Artus, C. G.; Zoller, T.; Cougot, N.; Basyuk, E.; Bertrand, E.; Filipowicz, W., Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science., 2005, 309 (5740), 1573-6.
80. Guo, C. J.; Pan, Q.; Cheng, T.; Jiang, B.; Chen, G. Y.; Li, D. G., Changes in microRNAs associated with hepatic stellate cell activation status identify signaling pathways. FEBS J., 2009, 276 (18), 5163-76.
81. Roderburg, C.; Urban, G. W.; Bettermann, K.; Vucur, M.; Zimmermann, H.; Schmidt, S.; Janssen, J.; Koppe, C.; Knolle, P.; Castoldi, M.; Tacke, F.; Trautwein, C.; Luedde, T., Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology.,2011, 53 (1), 209-18.
82. Dwivedi, R. S.; Herman, J. G.; McCaffrey, T. A.; Raj, D. S., Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int.,2011, 79 (1), 23-32.
83. Mann, J.; Oakley, F.; Akiboye, F.; Elsharkawy, A.; Thorne, A. W.; Mann, D. A., Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ., 2007, 14 (2), 275-85.
84. Rombouts, K.; Knittel, T.; Machesky, L.; Braet, F.; Wielant, A.; Hellemans, K.; De Bleser, P.; Gelman, I.; Ramadori, G.; Geerts, A., Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. J Hepatol., 2002, 37 (6), 788-96.
85. Mann, J.; Chu, D. C.; Maxwell, A.; Oakley, F.; Zhu, N. L.; Tsukamoto, H.; Mann, D. A., MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology.,2010, 138 (2), 705-14, 714 e1-4.
86. Roderburg, C.; Urban, G. W.; Bettermann, K.; Vucur, M.; Zimmermann, H.; Schmidt, S.; Janssen, J.; Koppe, C.; Knolle, P.; Castoldi, M.; Tacke, F.; Trautwein, C.; Luedde, T., Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology.,2011, 53 (1), 209-18.
87. Lakner, A. M.; Bonkovsky, H. L.; Schrum, L. W., microRNAs: fad or future of liver disease. World J Gastroenterol.,2011, 17 (20), 2536-42.
88. Karlsen, T. H.; Melum, E.; Franke, A., The utility of genome-wide association studies in hepatology. Hepatology.,2010, 51 (5), 1833-42.
89. Weber, S. N.; Wasmuth, H. E., Liver fibrosis: from animal models to mapping of human risk variants. Best Pract Res Clin Gastroenterol.,2010, 24 (5), 635-46.
90. Lee, Y.; Friedman, S. L., Fibrosis in the liver: acute protection and chronic disease. Prog Mol Biol Transl Sci.,2010, 97, 151-200.
91. Zimmer, V.; Lammert, F., Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol.,2011, 25 (2), 269-80.
92. Wallace, K.; Burt, A. D.; Wright, M. C., Liver fibrosis. Biochem J., 2008, 411 (1), 1-18.
93. Rovira, P.; Mascarell, L.; Truffa-Bachi, P., The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem., 2000, 7 (7), 673-92.
94. Neuberger, J.; Gunson, B.; Hubscher, S.; Nightingale, P., Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl., 2004, 10 (4), 488-91.
95. Zhao, C.; Chen, W.; Yang, L.; Chen, L.; Stimpson, S. A.; Diehl, A. M., PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun., 2006, 350 (2), 385-91.
96. Fiorucci, S.; Clerici, C.; Antonelli, E.; Orlandi, S.; Goodwin, B.; Sadeghpour, B. M.; Sabatino, G.; Russo, G.; Castellani, D.; Willson, T. M.; Pruzanski, M.; Pellicciari, R.; Morelli, A., Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther., 2005, 313 (2), 604-12.
97. Fiorucci, S.; Rizzo, G.; Antonelli, E.; Renga, B.; Mencarelli, A.; Riccardi, L.; Morelli, A.; Pruzanski, M.; Pellicciari, R., Cross-talk between farnesoid-Xreceptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther., 2005, 315 (1), 58-68.
98. Pockros, P. J.; Jeffers, L.; Afdhal, N.; Goodman, Z. D.; Nelson, D.; Gish, R. G.; Reddy, K. R.; Reindollar, R.; Rodriguez-Torres, M.; Sullivan, S.; Blatt, L. M.; Faris-Young, S., Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology., 2007, 45 (3), 569-78.
99. Poynard, T.; McHutchison, J.; Manns, M.; Trepo, C.; Lindsay, K.; Goodman, Z.; Ling, M. H.; Albrecht, J., Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology., 2002, 122 (5), 1303-13.
100. Dosanjh, A., Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. Eur J Pharmacol., 2006, 536 (3), 219-22.
101. Armendariz-Borunda, J.; Islas-Carbajal, M. C.; Meza-Garcia, E.; Rincon, A. R.; Lucano, S.; Sandoval, A. S.; Salazar, A.; Berumen, J.; Alvarez, A.; Covarrubias, A.; Arechiga, G.; Garcia, L., A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut., 2006, 55 (11), 1663-5.
102. Wright, M.; Goldin, R.; Hellier, S.; Knapp, S.; Frodsham, A.; Hennig, B.; Hill, A.; Apple, R.; Cheng, S.; Thomas, H.; Thursz, M., Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut., 2003, 52 (8), 1206-10.
103. Duplantier, J. G.; Dubuisson, L.; Senant, N.; Freyburger, G.; Laurendeau, I.; Herbert, J. M.; Desmouliere, A.; Rosenbaum, J., A role for thrombin in liver fibrosis. Gut., 2004, 53 (11), 1682-7.
104. Shiratori, Y.; Imazeki, F.; Moriyama, M.; Yano, M.; Arakawa, Y.; Yokosuka, O.; Kuroki, T.; Nishiguchi, S.; Sata, M.; Yamada, G.; Fujiyama, S.; Yoshida, H.; Omata, M., Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med., 2000, 132 (7), 517-24.
105. Ghiassi-Nejad, Z.; Friedman, S. L., Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol., 2008, 2 (6), 803-16.
106. Fu, Y.; Zheng, S.; Lin, J.; Ryerse, J.; Chen, A., Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol Pharmacol., 2008, 73 (2), 399-409.
107. Kang, Q.; Chen, A., Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells. Br J Pharmacol., 2009, 157 (8), 1354-67.
108. Houglum, K.; Venkataramani, A.; Lyche, K.; Chojkier, M., A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology., 1997, 113 (4), 1069-73.
109. Aleynik, S. I.; Lieber, C. S., Polyenylphosphatidylcholine corrects the alcohol-induced hepatic oxidative stress by restoring s-adenosylmethionine. Alcohol Alcohol., 2003, 38 (3), 208-12.
110. Nieto, N.; Cederbaum, A. I., S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-beta induction of the COL1A2 promoter. J Biol Chem., 2005, 280 (35), 30963-74.
111. Vercelino, R.; Crespo, I.; de Souza, G. F.; Cuevas, M. J.; de Oliveira, M. G.; Marroni, N. P.; Gonzalez-Gallego, J.; Tunon, M. J., S-nitroso- Nacetylcysteine attenuates liver fibrosis in cirrhotic rats. J Mol Med (Berl).,2010, 88 (4), 401-11.
112. Pinzani, M.; Rombouts, K., Liver fibrosis: from the bench to clinical targets. Dig Liver Dis., 2004, 36 (4), 231-42.
113. Rockey, D. C.; Chung, J. J., Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med., 1994, 42 (4), 660-70.
114. Chen, Z.; Qi, L.Z.; Zeng, R.; Li, H.Y.; Dai, L.J., Stem cells and hepatic cirrhosis. Panminerva Med., 2010,52, (2), 149-165.
115. Kisseleva, T.; Gigante, E.; Brenner, D.A., Recent advances in liver stem cell therapy. Curr Opin Gastroenterol., 2010, 26, (4), 395-402.
116. Takami, T.; Terai, S.; Sakaida, I., Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol., 2012, 28, (3), 203-208.
117. Aagaard, L.; Rossi, J. J., RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev., 2007, 59 (2-3), 75-86.
118. Cheng, K.; Yang, N.; Mahato, R. I., TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm., 2009, 6 (3), 772-9.
119. Hu, P. F.; Xie, W. F., Targeted RNA interference for hepatic fibrosis. Expert Opin Biol Ther., 2009, 9 (10), 1305-12.
120. Xia, J. R.; Liu, N. F.; Zhu, N. X., Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats. Int J Mol Sci., 2008, 9 (4), 638-61.
121. De Vriese, A. S.; Tilton, R. G.; Mortier, S.; Lameire, N. H., Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant., 2006, 21 (9), 2549-55.